GENERIC MEDICATIONS
Are manufacturers responsible for label changes if the FDA previously
found the generic to be bioequivalent to the brand-name drug?
GPhA Congratulates President-Elect Obama In congratulating Senator Obama on his election win, Kathleen Jaeger, president and CEO of the Generic Pharmaceutical Association (GPhA), said that Obama and the new Congress "must now tackle the serious challenges facing our economy, including rising health care costs" by increasing access to "affordable generic and biogeneric medicines.
FDA Sends Ranbaxy Warning Letters; Import Alert Issued The FDA has sent two Warning Letters to Ranbaxy Laboratories, Ltd.
While the November presidential and congressional elections are still many months away, it is widely expected that health care reform will be at the top of the domestic policy agenda in the upcoming fall campaign.
Q: While their approaches differ, both Democratic hopefuls Senators Barack Obama and Hillary Clinton are calling for reformation of the United States health care system by instituting a "universal health care" model.
Pharmacists should be familiar with the legal issues involved when they dispense a drug manufactured by a company other than the one that makes the brand name of the prescribed drug.
There is little debate that the Rx-to-OTC switch movement (when a prescription drug is reclassified to nonprescription or OTC status) has caused major changes in the pharmacy marketplace. When the patent on a prescription medication expires, the manufacturer typically experiences a dip in profits due to emerging competition from generics.
Pharmaceuticals are a large part of health care expenditures in the United States.
FDA Halts Marketing of Unapproved Hydrocone Products Companies marketing unapproved drug products containing the narcotic hydrocone must cease or they will be subject to enforcement action, the FDA announced.
The Drug Price Competition and Patent Term Restoration Act of 1984 is commonly referred to as the Waxman-Hatch Act , after the law's primary authors, Rep.
Generic drugs provide Americans with lower-cost alternatives to the escalating costs of brand name drugs.
For community pharmacists, when Uncle Sam says "AMP," it might as well stand for "Ain't My Price.
Pharmacies have an ever-growing number of generic suppliers that provide product selection and variety.
Senior adults, while the leading consumers of prescription and OTC medications, often present with confusion, frustration, and economic difficulties relating to the procurement of their medication.
Q: Many pharmacists have told us that reimbursements of Medicaid prescriptions based on AMP (average manufacturer price) instead of AWP (average wholesale price) will have devastating effects on their profits when it comes to dispensing generics.
When a medication becomes available as a generic, the patient is offered a comparably safe and effective but more affordable treatment option, compared to the brand name product.